Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Regadenoson is a selective, short-acting adenosine A2A receptor agonist (Ki = 1.1 nM for pig striatum A2A receptor). It increases coronary blood flow 3.4- to 3.8-fold with a half-time to reversal of 1.9-2.6 minutes in open-chest anesthetized pigs. Regadenoson is used to induce hyperemia (increased blood flow), particularly in the context of myocardial perfusion imaging. It has also been found to increase the delivery of compounds to the central nervous system through the blood-brain barrier in animals.
Regadenoson is supplied as a crystalline solid. A stock solution may be made by dissolving the regadenoson in the solvent of choice. Regadenoson is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of regadenoson in these solvents is approximately 14 and 10 mg/ml, respectively. Regadenoson is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, regadenoson should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Regadenoson has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Gao, Z., Li, Z., Baker, S.P., et al. J. Pharmacol. Exp. Ther. 298(1), 209-218 (2001).
Zhao, G., Linke, A., Xu, X., et al. J. Pharmacol. Exp. Ther. 307(1), 182-189 (2003).
Bhatti, S., Hakeem, A., Dhanalakota, S., et al. Eur. Heart J. Cardiovasc. Imaging 15(8), 933-940 (2014).
Verberne, H.J., Acampa, W., Anagnostopoulos, C., et al. Eur. J. Nucl. Med. Mol. Imaging 42(12), 1929-1940 (2015).
Carman, A.J., Mills, J.H., Krenz, A., et al. J. Neurosci. 31(37), 13272-13280 (2011).